Skip Navigation



Cardiovascular Research Advance Access [Accepted Manuscript] published online on November 26, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn325
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
82/2/261    most recent
cvn325v2
cvn325v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morello, F.
Right arrow Articles by Hirsch, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morello, F.
Right arrow Articles by Hirsch, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org.

Phosphoinositide 3-kinase signaling in the vascular system

Fulvio Morello*, Alessia Perino* and Emilio Hirsch

All from the Molecular Biotechnology Center, University of Torino, via Nizza 52, 10126 Torino, Italy

Corresponding author: Emilio Hirsch, Molecular Biotechnology Center, University of Torino, via Nizza 52, 10126 Torino, Italy; phone +39-011-6706425, fax +39-011-6706432; email emilio.hirsch{at}unito.it

Phosphoinositide 3-kinases (PI3Ks) are protein and lipid kinases activated by different classes of membrane receptors, including G-protein coupled and tyrosine kinase receptors. Several lines of evidence have uncovered specific roles for distinct PI3K isoforms in the vascular system in both physiology and disease. The present review will summarize and discuss the most recent advances regarding PI3K-Akt signaling in endothelial cells, vascular smooth muscle cells, platelets and inflammatory cells involved in the atherosclerotic process. Of interest, the development of novel isoform-selective PI3K inhibitor drugs offers a unique opportunity to selectively and differentially target PI3K-driven pathways in the vascular system and may give rise to new strategies for the treatment of cardiovascular diseases.

Time for primary review: 27 Days

* FM and AP equally contributed to this work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
J. S. Karliner and J. H. Brown
Lipid signalling in cardiovascular pathophysiology
Cardiovasc Res, May 1, 2009; 82(2): 171 - 174.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.